First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer (BIG)
Gut Microbiome Intervention With EXL01 in Combination With Nivolumab and FOLFOX as First-line Treatment for Patients With PD-L1 CPS ≥5 Metastatic Gastric Cancer: A Randomized GERCOR Phase II Study (BIG)
Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
This PHASE2 trial investigates Gastric Cancer and is currently actively recruiting participants. GERCOR - Multidisciplinary Oncology Cooperative Group leads this study, which shows 7 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Oct 2025 — Present [monthly]
Recruiting PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE2
-
Jul 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Jul 2025 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Jul 2024 — Aug 2024 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- GERCOR - Multidisciplinary Oncology Cooperative Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Angers, France , Avignon, France , Besançon, France , Bordeaux, France , Brest, France , Caen, France , Cholet, France , Clermont-Ferrand, France , Créteil, France , Dijon, France and 18 more locations